tbuckley/cabot-search huggingface dataset:
Aspirin for Dual Prevention of Venous and Arterial Thrombosis
Authors: Theodore E. Warkentin
Journal: New England Journal of Medicine (2012)

Aspirin is conventionally regarded as an agent that prevents arterial thrombosis, an effect mediated through inhibition of platelet cyclooxygenase-1, resulting in decreased synthesis of thromboxane A2 (platelet-activating eicosanoid). In high-risk patients, aspirin reduces by one quarter the frequency of arterial thrombosis.1 In 1977, aspirin (at a dose of 600 mg twice daily) was shown to reduce the risk of venous thrombosis when it was given to patients after they had undergone hip arthoplasty.2 Thirty-five years later, guidelines include aspirin as one option for preventing venous thromboembolism after orthopedic surgery.3 However, many experts regard aspirin as inferior therapy for this . . .
SP0192 How to Measure Comorbidity in the Research Setting - A Review of Available Instruments
Authors: J. Dekker
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Instruments to assess comorbidity are based on (i) review of medical charts (e.g. Charlson index), (ii) pharmacy data (e.g. RxRisk score), (iii) medical interview (e.g. Cumulative Index Illness Rating Scale, CIRS), (iv) self report (e.g. Self-Administered Comorbidity Questionnaire, SCQ), or (v) a screening tool or diagnostic test for a specific disease (e.g. Center for Epidemiologic Studies Depression scale, CES-D). A further distinction concerns simple counts of the number of diseases versus indices that weigh a range of diseases. The characteristics and relative advantages of these instruments will be discussed. The purpose of the study and feasibility are major criteria for selecting a specific instrument. The use of these instruments will be illustrated with studies on the impact of comorbidity on mortality, functioning, and medical management of rheumatic diseases. <h3>Disclosure of Interest</h3> None Declared
Stat Bite: Cervical Cancer Incidence in Younger Women
Authors: C. L. Kosary
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Stat Bite : Cervical Cancer Incidence in Younger Women Get access Carol L. Kosary Carol L. Kosary Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 22, 17 November 1993, Page 1798, https://doi.org/10.1093/jnci/85.22.1798 Published: 17 November 1993
EUS-Guided Biliary Drainage for Malignant Biliary Duct Obstruction: Yokohama City University Experience
Authors: Kubota Kensuke, Ryo Ga, Kato Shingo, Watanabe Seitro, Kaneko Takashi, Shimamura Takeshi, Kobayashi Noritoshi, Sugimori Kazuya, Maeda Shin, Nakajima Atsushi
Journal: Endoscopy (2011)

Background: For patients who had a failed ERCP, EUS-guided biliary drainage (EUS-BD) has been developed as an alternative to percutaneous method. Aim: To evaluate technical and clinical outcomes of EUS-BD in our institute. Methods: Retrospective study of consecutive patients who following failed ERCP underwent EUS-BD at Yokohama City University Hospital. EUS-guided transluminal (transgastric or transduodenal) biliary stenting was performed. An echoendoscope was inserted into the stomach or the duodenal bulb to puncture the bile duct by a 19-gauge needle. After insertion of a 0.035-inch guide wire, the puncture hole was dilated by dilation catheters (6&7Fr). A straight plastic stent (7Fr) was placed to make hepaticogstrostomy or choledochoduodenostomy. The main outcome measures were rate of technical success and safety profile of EUS-BD. Results: 6 patients underwent EUS-BD. 5 patients were carcinomas in periampullary lesion and one was a metastatic biliary tumor due to colon cancer. Reason for failure at ERCP were failed cannulation (distorted ampulla) in 4 patients, inability to identify the papillary orifice in one and duodenal mass precluding access to the ampulla in one. The access routes for the transluminal drainage were transgastric in one patient and transduodenal in 5. EUS-BD was technically successful in 4 of 6 patients (66.7%). Two failure cases were treated by percutaneous transhepatic gallbladder drainage. Complications were encountered in 4 of 6 patients (66.7%) who underwent EUS-BD via the transluminal approach that include bleeding required transfusion (n=1), self-limited bile leak (n=1), self-limited perforation (n=1) and stent migration (n=1). No procedure-related deaths occurred. Patients were followed-up for average 212 days. During the follow-up, 3 patients died while 1 are actually alived and two patients required endoscopic re-interventions included metallic stenting. Conclusions: EUS-BD is technically feasible for our institute, however, the rate of complication is high. EUS-BD may be a useful procedure for treatment obstructive jaundice when ERCP fails, but required skill and dedicated devices for technical success and to reduce the complications.
Hormones Influence on Cancers Still Foggy
Authors: D. Holzman
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Hormones Influence on Cancers Still Foggy Get access David Holzman David Holzman Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 16, 16 August 1995, Pages 1208–1209, https://doi.org/10.1093/jnci/87.16.1208 Published: 16 August 1995
A new method for placement of covered colorectal stents in the proximal colon using double balloon enteroscopy
Authors: M. Fähndrich, M. Sandmann, M. Heike
Journal: Endoscopy (2011)

A 62-year-old patient was admitted for a persisting colocutaneous fistula in the transverse colon following relocation of a double-barreled anus praetor transversalis and resultant stenosis. Because of the presence of a frozen abdomen, owing to multiple previous surgeries, we opted for endoscopic intervention. To safely and easily place a routine, covered colorectal stent, in the absence of appropriate, available through-the-scope devices and in the presence of the excessive postsurgical scarring with fixed and adherent loops of the pelvic part of proximal transverse colon, we used the double-balloon enteroscopy procedure with a technical modification. A Savary guide wire (Cook Medical, Bloomington, Indiana, USA) was advanced through the working channel of an enteroscope over the stenosis in the area of the transverse colon. After completing threading and retracting the overtube maximally, the enteroscope was removed from the overtube. Then the overtube was cut for three-quarters of its circumference in the area of the anus ([Fig. 1]). Care was taken that the pressure line for the balloon remained intact. It was now possible to advance the covered colorectal stent via the Savary guide wire and through the overtube ([Fig. 2]), under X-ray guidance, up to the stenosis and open the stent in this position ([Fig. 3]). A similar technique has been described by Fähndrich et al. for endoscopic intervention using double balloon enteroscopy in the bile duct region after Roux-en-Y reconstruction [1].
Pancreatic cysts with borderline CEA: Ten year single center experience
Authors: C Naumann
Journal: Endoscopy (2011)

Background: Pancreatic cysts include pseudocysts and serous and mucinous neoplasms. Mucinous neoplasms exhibit variable malignant potential. This makes management of high-risk surgical patients difficult and underlies the importance of differentiating between cysts. Identifying cysts by morphology and cytology has poor results. In one study, CEA cutoff of 192ng/mL provided the greatest accuracy (0.79) in differentiating mucinous and nonmucinous cysts. A pooled analysis showed that CEA <5ng/mL suggests nonmucinous and >500ng/mL suggests mucinous. The etiology, natural history, and management of cystic lesions with borderline CEA is unknown. We sought to evaluate our population with borderline cystic CEA.
Pulmonary Infiltrates, Asthma and Eosinophilia Due to<i>Ascaris suum</i>Infestation in Man
Authors: James A. Phills, A. John Harrold, Gabriel V. Whiteman, Lewis Perelmutter
Journal: New England Journal of Medicine (1972)

Four male students who had been exposed to a massive dose of Ascaris suum ova, a parasite that is endemic to pigs, manifested the clinical picture of pulmonary infiltrates with eosinophilia and asthma. The two patients with the most widespread pulmonary infiltrates also had elevated IgE immunoglobulin levels, IgM precipitating antibody to A. suum antigen, and the most marked eosinophilia, thus suggesting the participation of an immune reaction in the pathogenesis of both the pulmonary lesions and the eosinophilia. The immune response may also have had a protective function since the patients with the most marked immune response to the ascaris antigen also had a minimal worm burden.
Biological Target Volume Overlapping Segmentation System Method for Avoiding False-Positive PET Findings in Assessing Response to Neoadjuvant Chemoradiation Therapy in Rectal Cancer
Authors: Anna Margherita Maffione, Sotirios Chondrogiannis, Maria Cristina Marzola, Lucia Rampin, Gaia Grassetto, Alice Ferretti, Elena Bellan, Carlo Capirci, Patrick M Colletti, Domenico Rubello
Journal: Clinical Nuclear Medicine (2013)

FDG PET/CT has a recognized high predictive power to assess the response to neoadjuvant chemoradiation therapy (CRT) in patients affected by locally advanced rectal cancer (LARC), but a relatively high number of false-positive findings decrease its specificity: with the aim to solve this problem, a new method of imaging analysis is here proposed.The new method here described, named Biological target volume (BTV) Overlapping Segmentation System (BOSS), has been applied on 24 consecutive patients with LARC that were all previously classified as nonresponders to CRT by means of the response index criterion that is adopted in our center. The BOSS method is based on the quantification of the amount of superimposition between pretreatment and posttreatment BTV. All BTVpre was down using a threshold of 60% of SUVmax in the tumor (BTV60). The results (overlap volumes and percentage of overlap volumes) were then matched up with postoperative pathology classified by the Mandard's tumor regression grade (TRG) system.Eleven patients were classified as responders (TRG1-2) and 13 as nonresponders (TRG 3-5). Among all the results obtained by BOSS method, only the percentage of overlap volume data between BTV60 and BTVpost (%Over_60) was able to correctly distinguish between responders and nonresponders. In our experience, a cutoff of 56% on the %Over_60 provided the best results in terms of true negative (11 cases), true positive (12 cases), false negative (1 case), and false positive (none).This new method, we developed, appears able to unmask the false-positive cases, improving the specificity of FDG PET/CT to predict the response to CRT patients with LARC.
Abstract 1666: Targeting tumor-initiating cells for the treatment of hepatocellular carcinoma
Authors: Zhiqian Zhang, Wei Zhao, Limin Wang, Haibo Han, Baocai Xing, Jiyou Li, Yu Wang
Journal: Cancer Research (2011)

Abstract Tumor-initiating cells (TICs) or so-called cancer stem cells (CSCs) are a minor subpopulation of poor differentiated cells that are responsible for tumor initiation, maintenance, and spreading. Hence, eliminating these cells is supposed to be an effective way of the treatment of cancer. By immunizing mice with TIC-enriched hepatocellular carcinoma (HCC) cells (Xu XL, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogensis. 2010; 31:167-74.) and by subsequent hybridoma technique, we have obtained an antibody 1B50-1, which recognizes the antigen of a 150 KD ion channel-composing protein. Despite the percentage of 1B50-1 positive cells varies from &amp;lt;1% to ∼90% in established hepatocellular carcinoma cell lines, the administration of this antibody by i.p. injection at a dose of 40mg/kg could suppress the growth of HCC cell lines’ engraftments in NOD/SCID mice with an inhibition rate that could be as high as 87%, comparing with control groups. Furthermore, 100 of 1B50-1 positive cells, but not the negative compartments, from several HCC cell lines were sufficient to initiate tumor growth in NOD/SCID mice, and displayed self-renewal ability as demonstrated by serial transplantation assay in mice. The 1B50-1 positive cells also expressed higher levels of Nanog, Sox-2, and Oct 4 than the negative ones. Immunohistochemical staining of 29 HCC specimen with 1B50-1 has revealed that only a small population of positive cells were scattered in 16 HCC tissues, and that these cells with similar distribution pattern were only found in 4 out of 12 paracancerous tissues. These data suggest that the antigen for 1B50-1 is a new marker for HCC tumor-initiating cells, and that it is a promising target for HCC molecular therapy. 1B50-1 is worthy of further developing into drug for the treatment of HCC. Funding: This study was supported by the National Basic Research Program of China (973 Program, No 2010CB529402), National Natural Science Foundation of China, and “863” Program (2008AA02Z108). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1666. doi:10.1158/1538-7445.AM2011-1666
FRI0428 The Weaker Sex: Characterization of Gender Disparities in A Nationwide Lupus Registry (REUMA.PT LES): Table 1.
Authors: M.J. Gonçalves, S. Sousa, L. Inês, C. Duarte, J. Borges, C. Silva, V.C. Romão, G. Terroso, M. Cerqueira, A. Raposo, M. Bernardes, C. Macieira, G. Sequeira, A. Barcelos, J. Canas da Silva, L. Costa, J. Pereira da Silva, L. Miranda, J. Da Silva, H. Canhao, M.J. Santos
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is characterized by female predominance with male to female ratio around 1:10. Differences regarding clinical manifestations, disease activity, damage and mortality between men and women with SLE have been reported. Overall it is recognized that gender may affect SLE phenotype, but results concerning disease severity and prognosis are still a matter of debate. <h3>Objectives</h3> Characterization of Portuguese SLE male patients, focusing demographic, clinical, and laboratorial features. <h3>Methods</h3> All SLE patients from the Portuguese Lupus Register, Reuma.pt/LES were included. Demographic, clinical and therapeutic data were analyzed upon records from the last visit. Student t-tests, chi-square tests and Fisher9s exact tests were used to compare male and female patients. Analyses were further adjusted to age and disease duration. <h3>Results</h3> Of the 1510 SLE patients registered in Reuma.pt/LES, 122 (8%) are men. Male patients had later onset (39.4±20.6y vs 35.6±14.1y; p=0.005) and shorter disease duration (10.7±7.6y vs 14.1±9.0 y; p=0.0001). Mean current age, racial distribution and education level was similar in the two groups. Serositis, renal involvement and hemolytic anemia were more prevalent in men while, photosensitivity, alopecia, oral ulcers and arthritis were more commonly found in women (Table 1). Thyroid disease was more frequent in women (11.4 vs 2.3%). Cardiovascular risk factors had a similar distribution between these groups. Accumulated damage assessed by the SLICC damage index (SDI) and disease activity, assessed by SLEDAI-2K at last visit were similar in the two groups, with adjustment to age and disease duration. Antimalarial drugs and steroids were used more frequently in women. <h3>Conclusions</h3> Male patients with SLE are older at disease onset and present a distinct phenotype with less cutaneous, mucous membranes and articular manifestations. However, disease outcome evaluated by the SDI is comparable in men and women, which is in line with observations from other European cohorts. The acknowledgement of the effect of gender on disease manifestations may help physicians in the timely introduction of an appropriate care. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4615
ACL injuries in men's professional football: a 15-year prospective study on time trends and return-to-play rates reveals only 65% of players still play at the top level 3 years after ACL rupture
Authors: Markus Waldén, Martin Hägglund, Henrik Magnusson, Jan Ekstrand
Journal: British Journal of Sports Medicine (2016)

Studies investigating the development of ACL injuries over time in football are scarce and more data on what happens before and after return to play (RTP) are needed.To investigate (1) time trends in ACL injury rates, (2) complication rates before return to match play following ACL reconstruction, and (3) the influence of ACL injury on the subsequent playing career in male professional football players.78 clubs were followed between 2001 and 2015. Time trend in ACL injury rate was analysed using linear regression. ACL-injured players were monitored until RTP and tracked for 3 years after RTP.We recorded 157 ACL injuries, 140 total and 17 partial ruptures, with a non-significant average annual increase in the ACL injury rate by 6% (R(2)=0.13, b=0.059, 95% CI -0.04 to 0.15, p=0.20). The match ACL injury rate was 20-fold higher than the training injury rate (0.340 vs 0.017 per 1000 h). 138 players (98.6%) with a total rupture underwent ACL reconstruction; all 134 players with RTP data (4 players still under rehabilitation) were able to return to training, but 9 of them (6.7%) suffered complications before their first match appearance (5 reruptures and 4 other knee surgeries). The median layoff after ACL reconstruction was 6.6 months to training and 7.4 months to match play. We report 3-year follow-up data for 106 players in total; 91 players (85.8%) were still playing football and 60 of 93 players (65%) with ACL reconstruction for a total rupture played at the same level.The ACL injury rate has not declined during the 2000s and the rerupture rate before return to match play was 4%. The RTP rate within a year after ACL reconstruction was very high, but only two-thirds competed at the highest level 3 years later.
Outbreak of Shiga toxin-producing E. coli O157 associated with consumption of watercress, United Kingdom, August to September 2013
Authors: N Launders, L Byrne, N Adams, K Glen, C Jenkins, D Tubin-Delic, M Locking, C Williams, D Morgan, None on behalf of the Outbreak Control Team
Journal: Eurosurveillance (2013)

Binary file ES_Abstracts_Final_ECDC.txt matches
AB0168 Therapeutic effects of sunitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a murine arthritis model
Authors: K. Furuya, Y. Kaku, K. Yoshida, K. Joh, D. Kurosaka
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Angiogenesis, the formation of new blood vessels, is recently considered as a key event and a therapeutic target of the pannus formation in rheumatoid arthritis<sup>1)</sup>. <h3>Objectives</h3> The purpose of this study was to confirm the inhibitory effects of sunitinib, an angiogenesis inhibitor that targets vascular endothelial growth factor receptor (VEGFR) tyrosine kinase<sup>2)</sup>, on arthritis in mice with type II collagen-induced arthritis (CIA). <h3>Methods</h3> Sunitinib at 30 or 60 mg/kg/day was intraperitoneally administered to mice with CIA. We compared the arthritis score, pathological score, bone density, and synovial microvascular density between the control and treatment groups. <h3>Results</h3> In the sunitinib-treated groups, the arthritis score decreased in a dose-dependent manner in comparison with the control group. Furthermore, improvement in the pathological score, inhibition of loss in the bone density, and a decrease in the synovial microvascular density were noted. <h3>Conclusions</h3> An angiogenesis inhibitor, sunitinib, inhibited arthritis in a murine CIA model. This compound may be useful for treating arthritis. <h3>References</h3> Szekanecz Z, Koch AE. Angiogenesis and its targeting in rheumatoid arthritis. Vascular pharmacology 2009 Jul;51(1):1-7. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical cancer research: an official journal of the American Association for Cancer Research 2003 Jan;9(1):327-331 <h3>Disclosure of Interest</h3> None Declared
HIGHER LEVELS OF ASYMMETRIC DIMETHYLARGININE ARE ASSOCIATED WITH LOWER FRACTIONAL FLOW RESERVE AFTER ORTHOTOPIC HEART TRANSPLANTATION
Authors: Rushi Parikh, Kiran Khush, Helen Luikart, Vedant Pargaonkar, Yuhei Kobayashi, Janghoon Lee, Seema Sinha, Garrett Cohen, Hannah Valantine, Alan Yeung, William Fearon
Journal: Journal of the American College of Cardiology (2016)
IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB
Authors: P. French, L. Erdem-Eraslan, J. M. Kros, H. M. Oosterkamp, A. M. E. Walenkamp, L. Beerepoot, M. Hanse, J. Buter, A. Honkoop, B. van der Holt, R. M. Vernhout, P. A. E. Sillevis Smitt, W. Taal, M. J. van den Bent
Journal: Neuro-Oncology (2014)

BACKGROUND: (blind field). METHODS: RNA expression profiling was performed using DASL (Illumina) on 185 samples of which 113 were derived from BELOB trial samples and 72 were used to test the performance of the platform. RNA sequencing was performed on 96 samples, 78 of which were from BELOB trial samples. RESULTS: The DASL and RNA-seqs platform both show a high concordance between technical and biological replicates. Importantly, they also show a high concordance with expression profiling on snap frozen tissue samples and have a highly similar sample assignment to one of seven ‘intrinsic glioma subtypes’ (IGS; molecular subtypes of glioma based on similarities in gene-expression profiles [PMID: 19920198]). Most BELOB samples are assigned to poor prognostic subtypes (IGS-18 and IGS-23). However, four patients were assigned to prognostically more favourable subtypes (IGS-9 and IGS-17). EGFR mutations were identified by RNA-seq in the majority of IGS-18 samples (60%) but in only 17% of samples assigned to IGS-23. Multiple EGFR mutations in the same sample were frequently observed. IDH1 mutations were identified by RNA-seq in three samples. Correlation with clinical patient performance and treatment arm is ongoing. CONCLUSIONS: DASL and RNA-seq perform well on RNA isolated from FFPE tissues stored (up to 20 years) in paraffin. We are currently correlating the expression data with clinical data from the BELOB trial. SECONDARY CATEGORY: n/a.